Browse Studies — Arctuva

Phase 1

A Phase 1/2 Clinical Study to Evaluate Safety, Tolerability, Biological Activity, and Initial Efficacy of Prime Editing (PM577a) for the Treatment of Wilson Disease (WD) in Adult and Adolescent Participants With at Least One Allele Harboring the p.H1069Q Mutation in ATP7B

The purpose of this study is to evaluate the safety, tolerability, biological activity, and initial efficacy of PM577a, an investigational Prime Editing therap…

Wilson DiseaseWilson's DiseaseWilsons Disease

Estimated

~$150 – $4,200

Actual pay is set by the research site.